Crossmark

Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors

Crossref DOI link: https://doi.org/10.1007/s12072-022-10450-4

Published Online: 2022-12-29

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lei, Jin

Yan, Tao

Zhang, Linzhi

Chen, Bowen

Cheng, Jiamin

Gao, Xiaoqiang

Liu, Zherui

Li, Yinyin

Zuo, Shi

Lu, Yinying
Funding

Funding for this research was provided by:

Science, Technology and Innovation Commission of Shenzhen Municipality (KCXFZ202002011006448)
License Information

Text and Data Mining valid from 2022-12-29

Version of Record valid from 2022-12-29
More Information

Article History

Received: 15 September 2022

Accepted: 4 November 2022

First Online: 29 December 2022

Declarations

:

: The Jin Lei, Tao Yan, Linzhi Zhang, Bowen Chen, Jiamin Cheng, Xiaoqiang Gao, Zherui Liu, Yinyin Li, Shi Zuo, and Yinying Lu declare no conflicts of interest that pertain to this work.

: All patients signed informed consent forms and received ethical support.

Document is current

Any future updates will be listed below